Our attorneys have filed a mass tort lawsuit on behalf of individuals who took the blood thinner Xarelto (rivaroxaban) and suffered significant bleeding events. Pharmaceutical firms, such as the makers of Xarelto, have a duty to ensure that their drugs are reasonably safe for use – and failure to accomplish so could be grounds for compensation. Our lawyers are working challenging to have these hurt by the drug the compensation they may be entitled to.
While bleeding is really a typical complication associated with anticoagulants, it has been alleged that Xarelto is a lot more hazardous than conventional blood thinners because no antidote exists to reverse its blood-thinning effects. This indicates that, in the occasion of an emergency, patients could be at danger for irreversible bleeding troubles, like life-threatening internal and gastrointestinal hemorrhaging.
In the event you or a loved 1 suffered a critical bleeding occasion soon after taking Xarelto, you might have legal recourse. For a lot more data, speak to us right now to have your case reviewed, totally free of charge.
Compensation Possibilities
xarelto-compensation-photoThe plaintiffs in these lawsuits are looking for compensation from Bayer and Janssen for previous and future healthcare bills, lost wages, pain and suffering and, in cases of death, funeral costs. Additionally, they’re seeking punitive damages, that are usually awarded to punish the defendant and deter other companies from acting similarly.
Why Are Lawsuits Getting Filed?
Bayer and Johnson & Johnson’s Janssen Pharmaceuticals, Inc. are facing several Xarelto lawsuits alleging that the drug is hazardous and defective. The plaintiffs claim that, unlike classic anticoagulants (e.g. warfarin, Coumadin) whose blood-thinning effects can be reversed using vitamin K, there is no antidote available for Xarelto. Simply because of this, the lawsuits claim, doctors have no effective signifies of stopping Xarelto users from bleeding in the occasion of an emergency. Plaintiffs within the lawsuits allege serious and fatal injuries, including cerebral hemorrhaging and gastrointestinal bleeds, from use of the drug.
In addition to these risks, lawsuits against Bayer and Johnson & Johnson’s Janssen Pharmaceuticals are alleging:
The manufacturers of Xarelto marketed the drug as a superior within the field of anticoagulants despite studies finding higher rates of gastrointestinal (GI tract) bleeding and transfusions in Xarelto users than users of certain competitors.
The makers of the drug continue to market Xarelto as a secure anticoagulant option.
Doctors and health-related staff were not properly made aware of methods to stabilize and treat a Xarelto user in the occasion of a bleeding complication.
Users of Xarelto were not adequately warned of the health risks of suffering a fatal bleeding event.
Xarelto is linked to serious bleeding complications, excessive blood loss, intracranial hemorrhaging, eye bleeding (vitreous hemorrhage), stomach bleeding, gastrointestinal bleeding, wound infections from inhibited clotting, and lack of effectiveness in preventing dangerous clotting.
Visit this page for more information on the alleged health risks of Xarelto.
Multidistrict Litigation Trial Dates Set
The attorneys within the Complex Litigation Group have filed lawsuits on behalf of injured clients. The claims will proceed through multidistrict litigation (MDL), which currently entails four trials, scheduled for Fall 2016, in which random groups of plaintiffs will be chosen to represent click the up coming post group.
